Literature DB >> 20035719

Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation.

Shafaqat Ali1, Dang Quan Nguyen, Werner Falk, Michael Uwe Martin.   

Abstract

IL-33 is a member of the IL-1 family of cytokines with dual function which either activates cells via the IL-33 receptor in a paracrine fashion or translocates to the nucleus to regulate gene transcription in an intracrine manner. We show that full length murine IL-33 is active as a cytokine and that it is not processed by caspase 1 to mature IL-33 but instead cleaved by caspase 3 at aa175 to yield two products which are both unable to bind to the IL-33 receptor. Full length IL-33 and its N-terminal caspase 3 breakdown product, however, translocate to the nucleus. Finally, bioactive IL-33 is not released by cells constitutively or after activation. This suggests that IL-33 is not a classical cytokine but exerts its function in the nucleus of intact cells and only activates others cells via its receptor as an alarm mediator after destruction of the producing cell. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035719     DOI: 10.1016/j.bbrc.2009.12.107

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  35 in total

Review 1.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

2.  IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G.

Authors:  Emma Lefrançais; Stephane Roga; Violette Gautier; Anne Gonzalez-de-Peredo; Bernard Monsarrat; Jean-Philippe Girard; Corinne Cayrol
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  Borrelia species induce inflammasome activation and IL-17 production through a caspase-1-dependent mechanism.

Authors:  Marije Oosting; Frank L van de Veerdonk; Thirumala-Devi Kanneganti; Patrick Sturm; Ineke Verschueren; Anneleen Berende; Jos W M van der Meer; Bart-Jan Kullberg; Mihai G Netea; Leo A B Joosten
Journal:  Eur J Immunol       Date:  2010-12-09       Impact factor: 5.532

4.  Dynamic role of epithelium-derived cytokines in asthma.

Authors:  Kathleen R Bartemes; Hirohito Kita
Journal:  Clin Immunol       Date:  2012-03-20       Impact factor: 3.969

Review 5.  Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2015-07

6.  IL-33 Exerts Neuroprotective Effect in Mice Intracerebral Hemorrhage Model Through Suppressing Inflammation/Apoptotic/Autophagic Pathway.

Authors:  Yuan Gao; Lu Ma; Cheng-Liang Luo; Tao Wang; Ming-Yang Zhang; Xi Shen; Huan-Huan Meng; Meng-Meng Ji; Zu-Feng Wang; Xi-Ping Chen; Lu-Yang Tao
Journal:  Mol Neurobiol       Date:  2016-07-12       Impact factor: 5.590

7.  The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation.

Authors:  Scott Napier Byrne; Clare Beaugie; Clare O'Sullivan; Sarah Leighton; Gary M Halliday
Journal:  Am J Pathol       Date:  2011-05-13       Impact factor: 4.307

8.  The chemical inhibitors of cellular death, PJ34 and Necrostatin-1, down-regulate IL-33 expression in liver.

Authors:  Muhammad Imran Arshad; Claire Piquet-Pellorce; Aveline Filliol; Annie L'Helgoualc'h; Catherine Lucas-Clerc; Sandrine Jouan-Lanhouet; Marie-Thérèse Dimanche-Boitrel; Michel Samson
Journal:  J Mol Med (Berl)       Date:  2015-03-08       Impact factor: 4.599

Review 9.  Control of innate and adaptive immunity by the inflammasome.

Authors:  Ceren Ciraci; John R Janczy; Fayyaz S Sutterwala; Suzanne L Cassel
Journal:  Microbes Infect       Date:  2012-07-24       Impact factor: 2.700

10.  Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages.

Authors:  Amrita D Joshi; Sameer R Oak; Adam J Hartigan; William G Finn; Steven L Kunkel; Karen E Duffy; Anuk Das; Cory M Hogaboam
Journal:  BMC Immunol       Date:  2010-10-19       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.